Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,294.9
0.0 (0.00%)

 

  • STI Straits Times Index
    3,294.9
    0.0 (0.00%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,527.1
    -0.7 (-0.05%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    24,965.5
    13.2 (0.05%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,522.6
    -32.5 (-0.91%)
    Index delayed 15 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 805.0M
  • Value: 1,097.8M
  • Rise: 135
  • Fall: 158
  • Unch: 474

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Jiutian Chemical0.086+0.003
DISA0.009+0.001
ThaiBev0.660+0.005
The Place Hldg0.074+0.016
Geo Energy Res0.355+0.025
Sembcorp Marine0.083-
Arion Ent0.011+0.001
Singtel2.480+0.010
Oceanus0.029+0.001
Genting Sing0.775-0.005

World Indices

World Indices
Name Last Change
Nasdaq 13,768.9 -385.1
HSI 24,965.5 +13.2
HSCEI 8,787.3 +25.7
Jakarta 6,726.4 +99.5
Nikkei 225 27,522.3 -250.7
SSE Comp 3,522.6 -32.5
Shanghai A 3,691.5 -34.1
Shanghai B 286.2 -0.8
KOSPI 2,834.3 -28.4

Nikkei 225 updated at end-of-day. Other Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

COMPASS THERAPEUTICS INC COMPASS THERAPEUTICS
Updated on 21 Jan 2022 (End of trading day)
Last (USD): 2.420 Change: -0.260 High: 2.680 Remarks: -
Change (%): -9.70 Low: 2.390
Open 2.630 Yesterday's Close 2.6799999999999997
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 100,582 Cumulative Value

Company Background

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. immuno-oncology product candidates include a clinical-stage monoclonal antibody targeting solid tumors, a novel bispecific targeting PD-1 and PD-L1, and a portfolio of bispecific and monoclonal antibodies at various stages of pre-clinical development. The company was founded by Thomas J. Schuetz on March 20, 2018 and is headquartered in Cambridge, MA.

Click to show Stock Prices chart

Key Statistics

EPS (USD) a -0.30092 Trailing EPS (USD) b -0.79150 NAV (USD) c 0.2437
PE a - Trailing PE d - Price / NAV c 9.9302
Dividend Yield (%) e - Cash In Hand (USD) f 0.2602 Issued & Paid-up Shares g 98,031,600
Piotroski F Score 1 Market Cap (M) 237.236 Free Float (%) 51.3
Return on Equity (ROE) (%) h n.m. Revenue Growth (%) TTM i n.m.
Net Earnings Growth (%) j -263.856 Net Debt/Equity k Net Cash
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted based on Profit Attributable To Shareholders.
  2. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  3. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  4. Based on latest Full Year results announcement, adjusted for the current number of shares.
  5. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  6. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  7. Rounded to the nearest thousand. The figure pertains to the respective exchange the stock is listed on. Updated on 15 Nov 2021. Please click here for more information.
  8. Calculated based on Net Earnings / (Shareholders' Equity - Other Share Capital)
  9. Calculated based on (Current Year Revenue - Last Year Revenue) / Last Year Revenue
  10. Calculated based on (Current Year Earnings - Last Year Earnings) / Last Year Earnings
  11. Calculated based on (Long Term Debt + Short Term Debt - Cash and Short Term Investments)/(Shareholders' Equity - Other Share Capital)

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.340
-12.32 %
10 Days --0.840
-25.77 %
20 Days --0.630
-20.66 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference COMPASS THERAPEUTICS INC NASDAQ 237.236 - - 9.9302 -
Industry Pharmaceuticals: Major NASDAQ 1,985.769 79.460 91.614 2.6001 0.029
Local Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 183,139.080 57.302 124.500 4.6080 -
Local Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 129,489.629 9.224 18.699 1.7267 -
Local Peer ROYALTY PHARMA PLC NASDAQ 23,764.790 24.373 30.358 4.1023 0.490
Local Peer VIATRIS INC NASDAQ 17,572.437 - - 0.8312 -
Local Peer REPLIGEN CORP NASDAQ 10,162.579 169.585 85.487 5.9248 -
Local Peer EVOTEC SE SPON ADS EACH REP 0.50 ORD SHS NASDAQ 6,998.939 981.791 23.759 6.0836 -
Local Peer ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS NASDAQ 6,089.616 - - 5.2885 -
Local Peer LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS NASDAQ 5,992.504 - - 26.5309 -
Local Peer HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS NASDAQ 4,998.712 - - 5.0758 -
Local Peer CUREVAC NV NASDAQ 3,499.307 - - - -
Local Peer CEREVEL THERAPEUTICS HLDGS INC NASDAQ 3,723.598 - - 5.9191 -
Local Peer APELLIS PHARMACEUTICALS INC NASDAQ 3,405.770 - - -59.4069 -
Other Local Peers KARUNA THERAPEUTICS INC (NASDAQ), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), OPKO HEALTH INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), IMMUNITYBIO INC (NASDAQ), EQRX INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), TURNING POINT THERAPEUTICS INC (NASDAQ), ERASCA INC (NASDAQ), AMYLYX PHARMACEUTICALS INC (NASDAQ), KEROS THERAPEUTICS INC (NASDAQ), PROCAPS GROUP S.A. (NASDAQ), QUANTERIX CORPORATION (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), REATA PHARMACEUTICALS INC (NASDAQ), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), ATAI LIFE SCIENCES NV (NASDAQ), GH RESEARCH PLC (NASDAQ), NURIX THERAPEUTICS INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), ICOSAVAX INC (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), IGM BIOSCIENCES INC (NASDAQ), PHARVARIS NV (NASDAQ), PETIQ INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), ATEA PHARMACEUTICALS INC (NASDAQ), REPARE THERAPEUTICS INC (NASDAQ), CINCOR PHARMA INC (NASDAQ), KINNATE BIOPHARMA INC (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), CULLINAN ONCOLOGY INC (NASDAQ), KRONOS BIO INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), POINT BIOPHARMA GLOBAL INC (NASDAQ), FORMA THERAPEUTICS HLDGS INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), 2SEVENTY BIO INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), TRICIDA INC (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), MIND MEDICINE (MINDMED) INC (NASDAQ), VERU INC (NASDAQ), XILIO THERAPEUTICS INC (NASDAQ), ALLAKOS INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), TENAYA THERAPEUTICS INC (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), TARSUS PHARMACEUTICALS INC (NASDAQ), GENERATION BIO CO (NASDAQ), ESSA PHARMA INC (NASDAQ), GRITSTONE BIO INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), AC IMMUNE SA (NASDAQ), LANDEC CORP (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), PYXIS ONCOLOGY INC (NASDAQ), EVOLUS INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), ANNEXON INC (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), IMMUNIC INC (NASDAQ), PROVENTION BIO INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), OLEMA PHARMACEUTICALS INC (NASDAQ), XOMA CORP (NASDAQ), CITIUS PHARMACEUTICALS I